SCIENTIFIC PROGRAM Friday October, 26 th OPENING SESSION 16:40-17:00 Opening lectures on Infectious Diseases 17:00-19:00 Opening lectures on Infectious Diseases Dr. Gerardo Guillén (Director of Biomedical Research at CIGB, Cuba) 20:00-21:00 WELCOME COCKTAIL 1
Saturday October, 27 th Dengue Symposium Dr. Diana Coronel and Dr. Beatriz Sierra 8:30-09:00 Dr. Beatriz Sierra, Cuba Different clinical outcome in Dengue: natural selection? 09:05-09:35 Dr. Vivian Huerta, Cuba Dengue virus interactome in human plasma reveals a novel target to develop antiviral drugs against the viral complex 09:40-10:10 Dr. Diana Coronel, Mexico Dengvaxia vaccine: update 10:15-10:45 Dr. Lazaro Gil, Cuba An update on Dengue Vaccine Candidates: the Cuban experience 11:00-11:20 2
Saturday October, 27 th Dr. Oliver Pérez 11:20-11:45 Dr. Oliver Pérez, Cuba Challenging the adjuvant s Gaston definition 11:50-12:15 Dr. Annele Roque, Cuba Plants and marine algae as alternative sources for antiviral drugs 12:20-12:45 Dr. Oscar Ledea, Cuba Preclinical and Clinical evidences of the antibacterial and parasitical actions of OLEOZON 12:50-13:10 To be announced 13:15-14:30 14:30-16:00 POSTER SESSION 3
Sunday October, 28 th Viral Hepatitis Symposium Prof. Beat Meier and Prof. Eduardo Pentón 8:30-09:00 Dr. Anja Bo ckmann, France Solid-state NMR investigation of capsids and envelopes from the Hepatitis B particle 09:05-09:30 Dr. Guillermo Fernández, Cuba Five year follow-up of chronic hepatitis B patients immunized by nasal route with the therapeutic vaccine HeberNasvac 09:35-10:00 Dr. Jorge Aguiar, Cuba Robustness of a low cost HBV-DNA quantitative system, a potential partner in the introduction and follow-up of a novel therapeutic vaccine versus chronic hepatitis B 10:05-10:30 Dr. Julio C. Aguilar, Cuba HEBERNASVAC, crossroad of biotechnology, vaccinology and liver immunology 10:35-10:55 4
Sunday October, 28 th Viral Hepatitis Symposium Prof. Beat Meier and Prof. Eduardo Pentón 11:00-11:25 Prof. Eduardo Pentón, Cuba Clinical trials of Chronic Hepatitis B therapeutic vaccines and novel therapeutic agents under clinical development 11:30-11:55 Prof. Beat H. Meier, Switzerland Solid-state NMR of two nonstructural proteins of Hepatitis C 12:00-12:25 MSc. Santa M. Olivera, Cuba Hepatitis C preventive vaccine based on a chimeric protein strategy 12:30-14:00 14:30-16:00 POSTER SESSION 5
Monday October, 29 th HIV Symposium Dr. Mosef Benkirane and Dr. Celia Fernández 8:30-09:00 Dr. Marie-Lise Gougeon, France How Innate Immune Cells Contribute to the establishment of HIV reservoirs? 09:05-09:25 Dr. Enrique Iglesias, Cuba Safety assessment of the vaccine candidate TERAVAC-HIV- 1 in a phase I Therapeutic Clinical Trial 09:30-09:50 Dr. Ingrid Rodríguez, Cuba HIV-specific antibodies and cellular immune response after Teravac vaccination in seropositive patients 09:55-10:15 Dr. Celia Fernández-Ortega, Cuba A peptide that penetrates human cell lines inhibits the HIV replication through the modulation of vimentin 10:20-10:35 Dr. Monsef Benkirane, France Impact of 3D genome organization on HIV integration site selection 10:50-11:10 Dr. Luca Shytaj, Germany HIV-1 replication alters redox and iron metabolism to deplete the latency marker PML in CD4+ T-cells 6
11:15-11:45 Dr. Celia Fernández Ortega, Cuba Closing remarks, Selection of outstanding posters. 7